Benefits and challenges of implementing preemptive testing in pharmacogenetics: A case report

Area of Science:

• Pharmacogenomics
• Genetics
• Clinical Pharmacology

Background:

• Pharmacogenomics (PGx) testing is increasingly shifting from reactive (post-adverse drug reaction) to preemptive strategies.
• Current practices often involve PGx testing only when specific drugs are considered or after adverse events occur.
• A growing movement advocates for obtaining genetic information proactively before initiating medication.

Purpose of the Study:

• To explore the transition of pharmacogenomics testing from reactive to preemptive approaches in clinical settings.
• To illustrate the benefits of preemptive PGx testing through a patient case study.
• To identify challenges hindering the widespread implementation of preemptive PGx.

Main Methods:

• Literature review and synthesis of current trends in pharmacogenomics implementation.
• Case study analysis demonstrating the application of preemptive PGx in personalized treatment planning.
• Discussion of barriers to widespread adoption and potential solutions.

Main Results:

• Preemptive PGx testing, guided by genetic variants in drug metabolism, can personalize treatment plans.
• Key benefits include preventing drug toxicity, reducing trial-and-error prescribing costs, and improving patient engagement.
• Challenges include healthcare provider education gaps, data privacy concerns, and cost/reimbursement issues, especially in the US.

Conclusions:

• Widespread adoption of preemptive PGx testing requires addressing educational, privacy, and financial barriers.
• Overcoming these challenges is crucial to realizing the full potential of personalized medicine.
• Ensuring equitable access to preemptive PGx testing is essential for advancing patient care.